Back to search results

Social Determinants of Health Program for Liver Cancer

This study is looking at how social support can help people with a type of liver cancer called hepatocellular carcinoma (HCC). It's testing if offering rides to appointments (through Lyft), hotel stays for treatment visits (through Hyatt House LA), and meal delivery (through Project Angel Food LA) can help patients get their treatments on time. You might be able to join if you are an adult (18 or older) with HCC (stages A-C), are uninsured or have Medicaid, and are able to give informed consent. The main goal is to see how many participants start their cancer treatment within 90 days. This study is focused on improving access to care for underserved patients.

Study design
This is an interventional study with a planned enrollment of 75 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 90 days, looking at treatment uptake within that timeframe.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07568457

Social Determinants of Health HCC Trial

Not Yet Recruiting
NAAges 18+InterventionalHealth services
University of Southern California
~75 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Social Determinants of Health ProgramPatient Navigation

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with treatment uptake within 90 days
Measured over 90 days

Conditions

HCC - Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT07568457

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Keck Hospital of USC

    Los Angeles, Californiastudy coordinator listed

  • LA General Medical Center

    Los Angeles, Californiastudy coordinator listed

  • USC Norris Comprehensive Cancer Center

    Los Angeles, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Kali Zhou
[email protected]
323-452-2293
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (18 years or older)
Diagnosis of HCC (BCLC Stage A-C)
Uninsured or underinsured (i.e., Medicaid as primary or secondary insurance)
Able to provide informed consent

Exclusion

Non-HCC liver tumors
BCLC Stage D and/or Child Pugh C cirrhosis (latter unable to receive treatment due to poor liver function)
No plans for cancer treatment for any reason including patient refusal (best supportive care only)
Only oral systemic therapy planned (i.e., tyrosine kinase inhibitors)
Incarcerated patients or pregnant patients
Unable to provide informed consent

What this trial measures

  • Proportion of participants with treatment uptake within 90 days90 days

    The primary outcome is receipt of timely treatment for HCC defined as within 90 days of randomization